Global consumption patterns of combination hypertension medication: An analysis of pharmaceutical sales data from 2010–2021
Open Access
- 6 September 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (9) , e0003698
Abstract
Hypertension is the most significant risk factor for cardiovascular disease and mortality worldwide, affecting 1.3 billion adults. Global disparities in hypertension control are widening with low- and middle-income countries (LMIC) having the fastest growing rates of hypertension and low rates of control. Treatment for hypertension can be challenging, with multiple drug classes and dosing schedules. Combination antihypertensives have been suggested as a solution for their efficacy and potential to improve adherence. Global consumption of combination and non-combination antihypertensives across 75 countries and 2 regions from 2010 to 2021 was estimated using the IQVIA MIDAS database on pharmaceutical sales. Consumption rates were standardized using Standard Units (SUs) and analysed by high-income (HIC), upper-middle income (UMIC), and LMIC income classification. Global median consumption rate of all antihypertensives per 1000 inhabitants per day increased from 184.78 SUs in 2010 to 325.6 SUs in 2021, with HICs consistently having the highest rates. Median consumption rates of combination and non-combination antihypertensives increased across all country income groups but combination drugs were consumed at a lower rate and proportion. LMICs consumed a higher percentage of combination antihypertensives relative to non-combination (45.5%) than UMICs (24.3%) and HICs (24.4%) in 2021. While combination antihypertensives may be preferred for their potential for increased adherence and effectiveness, their global uptake is inconsistent. HICs consume less combination medication relative to non-combination, despite higher overall consumption rates of antihypertensives. LMICs show increasing use of combination medications, indicating a shift towards their use.Keywords
This publication has 26 references indexed in Scilit:
- Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational studyeClinicalMedicine, 2021
- Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019The Lancet, 2020
- Effectiveness of two‐drug therapy versus monotherapy as initial regimen in hypertension: A propensity score‐matched cohort study in the UK Clinical Practice Research DatalinkPharmacoepidemiology and Drug Safety, 2019
- Fixed-dose combination antihypertensive medicationsThe Lancet, 2019
- What’s new in the ESC 2018 guidelines for arterial hypertensionWiener klinische Wochenschrift, 2019
- Antihypertensive Drugs in Croatia: What Changes the Drug Usage Patterns?Clinical Therapeutics, 2018
- Seventeen-Year Nationwide Trends in Antihypertensive Drug Use in DenmarkThe American Journal of Cardiology, 2017
- A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertensionThe Lancet, 2016
- Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income CountriesJAMA, 2013
- The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settingsThe Lancet, 2006